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Abstract
Background:  The advantage of treatment interruptions (TIs) in salvage therapy remains
controversial. Regardless, characterizations of the correlates of CD4 count fall during TI are
important to identify since patients with virologic failure commonly stop antiretroviral (ARV)
therapy. The objective of this study was to determine the predictive value of pre-TI proliferative
capacity and cell surface markers for CD4 count change in HIV-infected patients experiencing
virologic failure before undergoing TI.
Methods:  Peripheral blood mononuclear cells (PBMCs) from 13 HIV-infected patients
experiencing virologic failure at baseline time points before the TI were tested for proliferation
using the 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution assay and a Gag p55
peptide pool, staphylococcus enterotoxin B (SEB), cytomegalovirus (CMV) recall antigen, and anti-
CD3 antibody as stimuli. CD28 and CD57 expression on CD4+ and CD8+ T-cells was measured.
Results: The median changes in the CD4+ T-cell count and viral load from baseline to the TI time
point corresponding to the CD4 count nadir were -44 cells/mm3 {Interquartile range (IQR) -17, -
104} and +85,332 copies/mL (IQR +11,198, +283,327), respectively. CD4+ T-cell proliferation to
CMV, pre-TI CD4+ T-cell count, and percent CD4+CD57+ cells correlated negatively with CD4
count change during TI (r = -0.59, p = 0.045, r = -0.61, p = 0.030 and r = -0.69, p = 0.0095,
respectively; Spearman correlation). The presence of HIV-specific proliferative responses was not
associated with a reduced decline in CD4 count during TI.
Conclusion: The use of pre-TI immune proliferative responses and cell surface markers may have
predictive value for CD4 count decline during TI.
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Background
Combination antiretroviral (ARV) therapy (cART) has rev-
olutionized the treatment of human immunodeficiency
virus (HIV) infection, which is now viewed as a chronic
and manageable disease with reduced rates of acquired
immunodeficiency syndrome (AIDS)-related events and
deaths [1]. However, the management of patients with
multi-drug resistant HIV remains challenging, requiring
the development of both new ARVs and novel treatment
strategies to optimize outcomes in these patients.
One strategy that has been assessed in the context of treat-
ing multi-drug resistant HIV is the use of a structured treat-
ment interruption (TI) [2-4]. In this setting, patients
remain off ARVs for an often pre-determined duration of
time prior to starting a new treatment regimen. The ration-
ale for TI is based on the hypothesis that withdrawal of
drug pressure may allow the re-emergence of wild-type
virus, which would be more susceptible to suppression
upon starting a new treatment regimen. In addition, TI
may be used to alleviate existing side-effects and re-moti-
vate the patient to adhere to subsequent therapy [2-4].
Despite the theoretical advantages, several concerns
remain regarding the use of TI as a therapeutic strategy.
Specifically, the eventual re-emergence of resistant virus
from latently infected cells upon restarting ARV may lead
to a rebound in viremia and an accompanying significant
fall in CD4 T-cell count [4]. The most rapid decline in
CD4 count is associated with the emergence of wild-type
virus and increased viral replication [2]. The fall in CD4
count potentially places patients at increased risk of devel-
oping opportunistic infections, as was observed in the
SMART trial, which investigated TIs as a therapeutic strat-
egy [4,5]. Therefore, TIs are currently not recommended as
a treatment strategy on a routine basis [4,5]. However, it
is worthwhile to characterize immune correlates of CD4
decline during a TI as patients may elect to stop ARV ther-
apy for various reasons, including virologic failure, pill
fatigue and excessive toxicity.
In this study, we examined several immunological param-
eters observed at baseline time points within 12 months
of TI to assess whether they were associated with the
extent of CD4 count change during TI. The immunologi-
cal parameters studied, which included the expression of
CD28 and CD57 on T-cells, as well as T-cell proliferative
potential, were selected because there existed a rationale
for their association with CD4 count loss and viral load
outcome during TI. The loss of CD28 expression on CD8
T-cells has been shown to correlate with HIV disease pro-
gression and loss of IL-2 production for autocrine prolif-
eration [6,7]. The expression of CD57 identifies
replicative senescence in HIV-specific T-cells, which are
unable to proliferate and have a history of increased cell
divisions [8,9]. HIV-specific proliferative potential is
maintained in HIV infected individuals with favourable
clinical outcomes such as long-term non-progessors and
successfully treated aviremic patients [10,11]. The objec-
tive of this retrospective study was to evaluate the correla-
tion between baseline T-cell proliferative capabilities and
phenotypic markers with CD4 count decline during a TI in
HIV-infected patients experiencing virologic failure.
Methods
Study Design
A retrospective study was carried out on cryopreserved
peripheral blood mononuclear cell (PBMC) samples from
13 HIV-infected patients experiencing virologic failure on
cART before undergoing a TI. PBMC from a single time
point within 12 months before the TI were used as the
baseline samples. All were receiving cART consisting of at
least 3-drugs prior to the TI, which lasted at least 2
months. Virologic failure was defined as having plasma
HIV-1 RNA level >5,000 copies/mL while taking cART
measured on 2 occasions at least 4 weeks apart. The
patients were followed at the Immune Deficiency Treat-
ment Centre of the McGill University Health Centre in
Montreal, Quebec, Canada. The study population
included all the individuals identified at this clinical site
who met the inclusion criteria and for whom frozen cell
samples were available using a database that is main-
tained in our centre where clinical test results are collected
at each clinic visit.
Proliferation assay and flow cytometry analysis of CD28 
and CD57 expression
Proliferative capacity was measured using the 5,6-carbox-
yfluorescein diacetate succinimidyl ester (CFSE, Molecu-
lar Probes) dilution assay. PBMCs were labeled with CFSE
at a final concentration of 5 µM and stimulated with a
pool of 122 HIV 15-mer peptides with 11 amino acid
overlaps corresponding to the HIV-1 HXB2 Gag p55
sequence (NIH AIDS Research and Reference Reagent Pro-
gram), cytomegalovirus (CMV) lysate (Advanced Biotech-
nologies Inc.), staphylococcus enterotoxin B (SEB)
(Sigma-Aldrich), and anti-CD3 (Research Diagnostics) for
6 days at 37°C. On day 6, samples were stained with phy-
coerythrin (PE) conjugated anti-CD4, allophycocyanin
(APC) conjugated anti-CD8, and peridinin chlorophyll
protein (PerCP) conjugated anti-CD3 (BD Biosciences).
The percent of CFSElo CD3+CD4+ and CD3+CD8+ T cells
was analyzed using a FACSCalibur instrument (BD Bio-
sciences) and FlowJo software (version 5.72; TreeStar).
Anti-CD28-PE and anti-CD57 conjugated fluorescein iso-
thiocyanate (FITC) were used to detect the percent of
CD4+ and CD8+ T-cells expressing CD28 and CD57.BMC Infectious Diseases 2008, 8:59 http://www.biomedcentral.com/1471-2334/8/59
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Statistical analysis
Statistical analyses were performed using GraphPad InStat
software (version 3.06; GraphPad). The significance of
correlations between percent CFSElo cells generated to
each stimulus, the percent of CD28+ and CD57+ T-cells
and the pre-TI CD4 count with changes in the absolute
number of CD4+ T-cells from the pre-TI time point to the
CD4 count nadir (CD4+ T-cell decline) during the TI were
assessed using the Spearman nonparametric correlation
test. In addition, CD4+ T-cell change during TI was
dichotomized based on the median into those with
greater versus lesser CD4 count loss. These subpoplula-
tions were compared for median percent CFSElo cells and
the median percent of CD28+ and CD57+ expression on
CD4+ and CD8+ T-cells using the Mann-Whitney test. All
tests for statistical significance were two-tailed and p val-
ues <0.05 were considered significant.
Results
Description of study population
The study subjects had a median age of 42 years (IQR, 40,
43) and 11 (85%) were male and 2 (15%) were female.
The median duration on ARV therapy was 8.5 years (IQR,
5.7, 10.7). The median number of previous ARV regimens
and number of ARV drugs being taken at baseline were 12
(IQR, 8, 16) and 4.0 (IQR 3, 5), respectively. Prior to
beginning a TI, 23% of patients were on a non-nucleoside
reverse transcriptase inhibitor (NNRTI)-based regimen,
46% on a protease inhibitor (PI)-based regimen, 23%
were on a regimen that included both PI- and NNRTI, and
8% were on a PI- and fusion inhibitor-based regimen. The
median baseline viral load, baseline CD4 count and CD4
count nadir during TI were 24,719 copies/mL (IQR,
12,581, 161,918), 171 cells/mm3 (IQR, 56, 264), and 28
cells/mm3 (IQR, 9, 72), respectively. The median CD4
count decline (baseline to nadir) during TI was -44 cells/
mm3 (IQR, -17, -104). The median time from the on-ther-
apy baseline CD4 count to the TI was 4.4 months (IQR,
2.3, 6.0) and from the on-therapy baseline CD4 count to
the CD4 count nadir during the TI was 5.7 months (IQR,
3.1, 7.5).
Baseline immune parameters and their association with 
CD4 count change during TI
Figure 1A shows flow cytometry contour plots generated
by measuring proliferation using a CFSE dilution assay in
PBMCs from 2 study patients, one who experienced a
CD4 count change during TI that was lower and the other
higher than the median for the study population tested.
The proliferative capacity of patient PBMC was screened
using a panel of stimuli including no stimulation as a neg-
ative control, SEB and anti-CD3 antibody as positive con-
trols, CMV lysate as a recall antigen and a Gag p55 peptide
pool as an HIV-specific antigen. Figure 1B shows data for
12 patients stimulated with CMV lysate and 13 patients
stimulated with the HIV Gag p55 peptide pool. One
patient could not be tested for proliferation to CMV lysate
due to an insufficient number of cells available. When the
percentage of CFSElo T-cells was plotted versus CD4 count
change from baseline to CD4 nadir during TI time points
we found a statistically significant negative correlation
between the percentage of CMV-specific CFSElo
CD3+CD4+ T-cells and CD4 count change (r = -0.59, p =
0.045; Spearman correlation test). We also noted a nega-
tive correlation between pre-TI CD4 count and CD4 count
change (r = -0.61, p = 0.030, Table 1). No significant rela-
tionship was observed between CMV-specific prolifera-
tion by CD8+ T-cells nor HIV Gag p55-specific
proliferation by either CD4+ or CD8+ T-cells with CD4
count change (Figure 1B and Table 1). We also did not
observe any significant association between CD4+ and
CD8+ T-cell proliferation to anti-CD3 and SEB with CD4
count change (Table 1).
Figure 2A shows flow cytometry contour plots for PBMC
from 2 patients stained for CD57 on CD3+CD8- cells,
which identify CD4+ T-cells. When results from all 13
patients were considered, we observed a negative correla-
tion between the percent of CD4+CD57+ cells at baseline
and CD4+ change during TI (r = -0.69, p = 0.0095; Spear-
man) (Figure 2B). All other phenotypic markers tested
including expression of CD57 on CD8+ T-cells and CD28
expression on CD4+ and CD8+ T-cells did not correlate
with CD4 count change during TI. (Table 1).
Patients were dichotomized into 2 groups by the median
CD4 count change (-44 cells/mm3) and pre-TI immune
parameters in the 2 subgroups were compared as another
way of questioning whether ability to proliferate to anti-
gens in the stimulatory panel or expression of CD57 or
CD28 on T-cells were differentially distributed in the sub-
groups with lesser versus greater CD4 decline during TI.
The group with a lesser CD4 count decline during TI
(good responders) had a median change of -17 cells/mm3
(IQR, -7, -23) whereas the group with the greater CD4 loss
(poor responders) had a median change of -107 cells/
mm3 (IQR, -88, -115). Both good and poor responders
had similar HIV-specific Gag p55 proliferative response
{0% (IQR, 0, 0) in the CD4+ compartment and 0.07%
(IQR, 0.03, 0.78) in the CD8+ compartment versus 0.11%
(IQR, 0, 0.42) in the CD4+ compartment and 0.12%
(IQR, 0.02, 0.25) in the CD8+ compartment for good and
poor responders; p = 0.22, p = 0.72 respectively; Mann-
Whitney test} (not shown). A non significant trend was
observed for the subpopulation with the lesser CD4+ T-
cell loss to have a lower percentage of CD4+CD57+ T-cells
at baseline compared with the group with higher CD4+ T-
cell decline {1.88% (IQR, 1.30, 2.74) versus 4.52% (IQR,
3.65, 5.04), p = 0.07; Mann-Whitney test}.BMC Infectious Diseases 2008, 8:59 http://www.biomedcentral.com/1471-2334/8/59
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Discussion
In this retrospective study, we showed that baseline CMV-
specific CD4+ T-cell proliferation, pre-TI CD4 count, and
percent CD4+CD57+ T-cells correlated negatively with
CD4+ count change during a TI in patients experiencing
virologic failure. Despite the known inverse association
between plasma viremia and HIV-specific T-lymphocyte
proliferative capacity, we found no association between
the presence of HIV-specific proliferative responses at
baseline and the extent of decline in CD4+ T-cells num-
bers during TI. In contrast, baseline CD4+ T-cell prolifera-
tion to CMV was an indicator of a larger decline in CD4
count during TI. Since more than 95% of HIV-infected
patients are also infected with CMV, the presence of the
endogenous CMV has the potential to activate and expand
CD4+ T-cells, rendering them permissive for HIV replica-
tion and susceptible to virus mediated destruction [12].
Further research is needed to determine whether this
mechanism underlies the association between CMV-spe-
cific proliferation and CD4+ T-cell decline during TI. One
way to test our theory would be to examine whether there
was a correlation between expression of immune activa-
tion markers such as CD38 and HLA-DR and proliferation
to CMV. Unfortunately limitations in availability of cell
numbers for these samples precluded including anti-
CD38 or anti-DR in our antibody panels. However, we do
recognize the importance of testing for CD38 and HLA-
DR and we recommend the investigation of these activa-
tion markers in any future studies. Our findings differ
from those of previous studies, in that baseline lympho-
proliferative response to recall antigens in the setting of a
TI initiated in early stage chronic HIV infection was a pre-
dictor of favorable virologic outcome following re-initia-
tion of cART [13]. The discrepancies observed could be
explained by the difference in the study population, dis-
ease stage, and endpoints measured.
Although pre-TI CD4 count nadir was not predictive of
CD4+ T-cell decline as shown in previous studies [14,15],
we observed that the pre-TI baseline CD4 count correlated
negatively with CD4+ T-cell decline during TI. The use of
CD4 count as a marker of clinical disease progression is
well established in HIV infection. In advanced HIV infec-
tion where the individuals experienced virologic failure to
all three ARV drug classes, baseline CD4 count was found
to be a strong predictor of short-term risk of AIDS and
death [16]. Here, we further underline the potential use of
CD4 count in the setting of TI before initiating ensuing
therapy.
In addition to using CD4 counts and viral loads to evalu-
ate clinical HIV disease progression, cell surface markers
including CD28 and CD57 have also been investigated.
Traditionally, CD28 has been defined as a senescence
marker whose loss of expression by T-cells during HIV
infection has been associated with disease progression [6].
Brenchley et al. demonstrated that the expression of CD57
rather than the loss of CD28 expression defined replica-
tive senescence [8]. They also showed that HIV-specific
CD8+ T-cells that expressed CD57 were more sensitive to
Table 1: Correlation between baseline immunological parameters and CD4 count change from baseline to nadir during TI
T-cell compartment Proliferative Stimulus/Phenotypic Markers 
Expression*
Correlation with CD4 count change from baseline to 
nadir during TI**
CD4 anti-CD3 -0.07 (p = 0.87)
SEB 0.43 (p = 0.30)
CMV -0.59 (p = 0.045)***
Gag p55 peptide pool -0.40 (p = 0.17)
%CD57+ -0.69 (p = 0.0095)***
CD57+ MFI -0.03 (p = 0.93)
%CD28 -0.38 (p = 0.19)
CD28+ MFI -0.18 (p = 0.55)
CD8 anti-CD3 -0.09 (p = 0.81)
SEB 0.14 (p = 0.75)
CMV -0.48 (p = 0.12)
Gag p55 peptide pool -0.01 (p = 0.96)
%CD57+ 0.01 (p = 0.97)
CD57+ MFI 0.29 (p = 0.34)
%CD28 0.33 (p = 0.27)
CD28+ MFI -0.10 (p = 0.73)
Baseline CD4+ count -0.61 (p = 0.030)***
Baseline viral load -0.35 (p = 0.24)
*CMV = cytomegalovirus lysate; SEB = streptococcus enterotoxin B; MFI = mean fluorescence intensity.
**Spearman nonparametric correlation test (p-value).
***p < 0.05BMC Infectious Diseases 2008, 8:59 http://www.biomedcentral.com/1471-2334/8/59
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Panel A shows representative FACS contour plots gated on CD3+ lymphocytes showing CD4+ and CD8+ proliferative  responses to no stimulation (negative control), SEB (superantigen), CMV (recall antigen) and Gag p55 peptide pool (HIV-spe- cific antigens) for a patient with a CD4 count change during TI that was lower than the median for the group (Patient #3) in the  left hand panels and a patient with a change in CD4 count during TI that was higher than the median for the group (Patient #1)  in the right hand panels Figure 1
Panel A shows representative FACS contour plots gated on CD3+ lymphocytes showing CD4+ and CD8+ pro-
liferative responses to no stimulation (negative control), SEB (superantigen), CMV (recall antigen) and Gag 
p55 peptide pool (HIV-specific antigens) for a patient with a CD4 count change during TI that was lower than 
the median for the group (Patient #3) in the left hand panels and a patient with a change in CD4 count during 
TI that was higher than the median for the group (Patient #1) in the right hand panels. The number in the box of 
each contour plot is the percentage of CFSElo cells, which is an indication of the level of proliferation that has occurred in 
response to that stimulus. In Panel B, results from all patients are plotted for which proliferation data was available. The per-
centage of CFSElo cells following stimulation is plotted on the y-axis and CD4 count change from baseline to nadir during TI on 
the x-axis. The left hand panels show the percentage of CFSElo cells in the CD4+ T cell compartment and the right hand panels 
the percentage of CFSElo cells in the CD8+ T cell compartment. The upper panels show proliferation to CMV lysate (n = 12) 
and the bottom panels to the HIV Gag p55 peptide pool (n = 13). Proliferation to CMV and the Gag p55 peptide pool was 
assessed on baseline time points. The line in each graph represents a trendline through the data points. Spearman nonparamet-
ric correlation tests were used to test the significance of the association between these parameters; and p values <0.05 were 
considered significant.
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activation-induced apoptosis. More recent data further
characterized CD4+CD57+ T-cells in HIV-infection as
proliferation-incompetent and associated with an
increased rate of spontaneous and activation-induced
apoptosis [9]. We examined the expression of both mark-
ers and found that the baseline percentage of
CD4+CD57+ T-cells correlated negatively with CD4 count
loss during TI. Moreover the subpopulation with a lesser
CD4+ T-cell decline during TI had a lower median per-
centage of CD4+CD57+ T-cells, although the difference
did not reach statistical significance when compared to
the subpopulation experiencing greater CD4+ T-cell loss
during TI. Exposure to high antigen levels due to virologic
failure in these patients may drive the CD4+ T-cell popu-
lation to express CD57, a marker of terminal differentia-
tion [9,17]. This CD4+CD57+ T-cells population
identified at baseline was potentially more susceptible to
cell death and could account for the greater CD4 decline
during the viral rebound see during TI.
Some of the limitations of this study include the small
sample size and the time interval between the baseline
time point at which immune parameters were tested the
start of TI. One individual was tested 11.3 months from
start of TI, 5 were tested between 3 and 6 months of TI ini-
tiation and the remainder were tested for immune param-
eters between 0.7 and 2.5 months from start of TI. While
it is possible that the measurements do not truly represent
the state of the immune system at the time treatment is
stopped, we contend that these investigations are still rel-
evant in the context of an exploratory retrospective study.
The immune parameters found to be of significance
should be further validated in a prospective study with
larger sample size and a synchronized baseline pre-TI time
point for every patient.
Conclusion
Our study identified immune parameters, which may pre-
dict CD4+ T-cell decline during a TI in the setting of viro-
logic failure. Results presented may have important
clinical implications for patients deciding to interrupt
ARV treatment. Further investigation with larger sample
size will be needed to fully evaluate these immune predic-
tors.
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Panel A shows FACS contour plots generated by staining PBMC from baseline time points from 2 study subjects Figure 2
Panel A shows FACS contour plots generated by staining PBMC from baseline time points from 2 study sub-
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group. Panel B shows the correlation between the percentage of CD4+CD57+ cells at baseline and CD4 count loss during TI 
for all 13 patients tested. Spearman nonparametric correlation tests were used to assess the significance of the association 
between these parameters; p values <0.05 were considered significant.
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